Bethesda, Maryland – October 4, 2021 – Evergreen Therapeutics announces that the CMC team, led by Evergreen CEO, Dr. Xin Du, visited its US partner, Pharmaceutics International, Inc. (Pii), and met with the project team to discuss the production of the new anti-coronavirus drug.
Dr. Du and his team visits Pii facility
During the meeting, Pii’s project leader introduced and explained the company's production site via video, during which Evergreen’s CMC team discussed possible issues and solutions regarding drug production with each of Pii’s production-line teams. Thereafter, the Evergreen CMC team, guided by Pii team members, also visited several facilities, including the cGMP manufacturing area, the formulation R&D lab, and the cGMP warehouse.
Evergreen’s visit to its partnership facility highlights the priority of coronavirus drug production to the Company, and how seriously it looks upon its mission of focusing on clinical needs to benefit patients worldwide. Evergreen anticipates its upcoming clinical Phase II and Phase III drug production.
Pii production plant
Pharmaceutics International, Inc. (Pii) was founded 25 years ago as a CDMO with headquarter in Maryland, USA. Pii boasts of a dedicated formulation development center, state-of-the-art analytical laboratories, and a highly advanced cGMP manufacturing facility, including multiple containment units for handling highly toxic compounds and cGMP production lines for oral and injectable products. Pii has extensive hands-on experience bringing new drugs from concept, to clinical stage, to commercialization, and its services include the analysis, technology transfer, and cGMP manufacturing of oral and injectable formulations.